We Are Crinetics
Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Read the Latest
November 15, 2024
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
Crinetics' management will participate in three upcoming investor conferences: the Evercore 7th Annual HealthConx Conference on December 3rd, the Citi Global Healthcare Conference on December 4th, and the Piper Sandler 36th Annual Healthcare Conference on December 5th.
November 12, 2024
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Crinetics to showcase pipeline advancements with neuroendocrine tumor candidates at the 2024 NANETS Annual Meeting.
Pipeline
We support patients, endocrinologists, and healthcare providers by finding better therapies for endocrine diseases and endocrine oncology such as:
- Acromegaly
- Carcinoid syndrome
- ACTH-dependent Cushing’s syndrome
- Congenital adrenal hyperplasia (CAH)
- Hyperparathyroidism
- Polycystic kidney disease
- Graves’ disease
- TED
- Diabetes
- Obesity
- Hyperinsulinism
Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Approved |
---|---|---|---|---|---|
Acromegaly
Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Approved |
---|---|---|---|---|---|
Acromegaly